IP Library Granted Patent US 11,129,883
Granted Patent B2
US 11,129,883 · App. 15/913,837 · Granted Sep 28, 2021

IL-15-based fusions to IL-12 and IL-18

Inventors: Warren D. Marcus (Miramar, FL); Robert Newman (Miramar, FL); Bai Liu (Cooper City, FL); Lijing You (Miramar, FL); Lin Kong (Miramar, FL); Peter Rhode (Miami, FL); Hing C. Wong (Weston, FL)
Assignee: Altor BioScience, LLC.
A61K39/00114A61K47/6811A61P35/00C07K14/54C07K14/5434C07K14/5443C07K14/715C07K16/283C12N15/62C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,129,883
App. No.
15/913,837
Granted
Sep 28, 2021
Kind
B2
Abstract

The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.

Claims (20)

1. An isolated soluble fusion protein complex comprising at least two soluble proteins, wherein

a first soluble protein comprises an interleukin-15 (IL-15) domain and an IL-12 domain, and a second soluble protein comprises an IL-18 domain and a soluble IL-15 receptor alpha sushi-binding domain (IL-15RαSu) fused to a homodimeric immunoglobulin crystallizable fragment (Fc) domain,

wherein the homodimeric immunoglobulin Fc domain comprises two monomers covalently linked by a disulfide bond, and

wherein the IL-15 domain of the first soluble protein binds to the IL-15RαSu domain of the second soluble protein to form a soluble fusion protein complex.

2. The soluble fusion protein complex of claim 1 , wherein the IL-12 domain comprises p40 and p35 subunits of IL-12.

3. The soluble fusion protein complex of claim 2 , wherein the p40 and p35 subunits of IL-12 are linked by a flexible polypeptide linker into a single-chain format.

4. The soluble fusion protein complex of claim 3 , wherein the first soluble protein comprises the amino acid sequence set forth in SEQ ID NO: 8.

5. The soluble fusion protein complex of claim 4 , wherein the second soluble protein comprises the amino acid sequence set forth in SEQ ID NO: 6.

6. The soluble protein complex of claim 1 , wherein the first soluble protein complex is covalently linked to the second soluble protein complex by a disulfide bond linking the Fc domain of the first soluble protein complex to the Fc domain of the second soluble protein complex.

7. The soluble fusion protein complex of claim 1 , wherein the first or second soluble protein further comprises a binding domain that binds to a disease antigen and/or an immune checkpoint or signaling molecule.

8. The soluble fusion protein complex of claim 7 , wherein the disease antigen is associated with neoplasia or infectious disease.

9. An isolated soluble fusion protein complex comprising at least two soluble proteins, wherein

a first soluble protein comprises an IL-15 domain and an IL-18 domain, and a second soluble protein comprises an IL-12 domain and a soluble IL-15RαSu fused to a homodimeric immunoglobulin Fc domain,

wherein the homodimeric immunoglobulin Fc domain comprises two monomers covalently linked by a disulfide bond, and

wherein the IL-15 domain of the first soluble protein binds to the IL-15RαSu domain of the second soluble protein to form a soluble fusion protein complex.

10. The soluble fusion protein complex of claim 9 , wherein the IL-12 domain comprises p40 and p35 subunits of IL-12.

11. The soluble fusion protein complex of claim 10 , wherein the p40 and p35 subunits of IL-12 are linked by a flexible polypeptide linker into a single-chain format.

12. The soluble fusion protein complex of claim 11 , wherein the first soluble protein comprises the amino acid sequence set forth in SEQ ID NO: 4.

13. The soluble fusion protein complex of claim 12 , wherein the second soluble protein comprises the amino acid sequence set forth in SEQ ID NO: 2.

14. The soluble protein complex of claim 9 , wherein the first soluble protein is covalently linked to the second soluble protein by a disulfide bond linking an Fc domain of the first soluble protein to an Fc domain of the second soluble protein.

Assignments (4)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
MERGER Recorded Jun 17, 2021
From: ALTOR BIOSCIENCE CORPORATION
To: ALTOR BIOSCIENCE LLC
Reel/Frame 056574/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2021
From: MARCUS, WARREN D.; NEWMAN, ROBERT G.; LIU, BAI; YOU, LIJING; KONG, LIN; RHODE, PETER
To: ALTOR BIOSCIENCE CORPORATION
Reel/Frame 056119/0910 →
CONSULTING AGREEMENT Recorded Apr 14, 2021
From: WONG, HING C.
To: ALTOR BIOSCIENCE, LLC
Reel/Frame 055929/0989 →
Cited By (5)
US 12,233,116 US 12,343,379 US 12,403,180 US 12,594,325 US 12,685,759